236 related articles for article (PubMed ID: 29567478)
1. Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα.
Yamamoto Y; Takei K; Arulmozhiraja S; Sladek V; Matsuo N; Han SI; Matsuzaka T; Sekiya M; Tokiwa T; Shoji M; Shigeta Y; Nakagawa Y; Tokiwa H; Shimano H
Biochem Biophys Res Commun; 2018 May; 499(2):239-245. PubMed ID: 29567478
[TBL] [Abstract][Full Text] [Related]
2. Elucidation of Molecular Mechanism of a Selective PPARα Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations.
Kawasaki M; Kambe A; Yamamoto Y; Arulmozhiraja S; Ito S; Nakagawa Y; Tokiwa H; Nakano S; Shimano H
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31935812
[TBL] [Abstract][Full Text] [Related]
3. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
[TBL] [Abstract][Full Text] [Related]
4. Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate.
Sasaki Y; Raza-Iqbal S; Tanaka T; Murakami K; Anai M; Osawa T; Matsumura Y; Sakai J; Kodama T
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766193
[TBL] [Abstract][Full Text] [Related]
5. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
[TBL] [Abstract][Full Text] [Related]
6. The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.
Araki M; Nakagawa Y; Oishi A; Han SI; Wang Y; Kumagai K; Ohno H; Mizunoe Y; Iwasaki H; Sekiya M; Matsuzaka T; Shimano H
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30041488
[TBL] [Abstract][Full Text] [Related]
7. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
[TBL] [Abstract][Full Text] [Related]
8. Pemafibrate, a selective PPARα modulator, and fenofibrate suppress microglial activation through distinct PPARα and SIRT1-dependent pathways.
Ogawa K; Yagi T; Guo T; Takeda K; Ohguchi H; Koyama H; Aotani D; Imaeda K; Kataoka H; Tanaka T
Biochem Biophys Res Commun; 2020 Apr; 524(2):385-391. PubMed ID: 32005522
[TBL] [Abstract][Full Text] [Related]
9. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
Fruchart JC; Hermans MP; Fruchart-Najib J
Curr Atheroscler Rep; 2020 Jul; 22(8):43. PubMed ID: 32671476
[TBL] [Abstract][Full Text] [Related]
10. Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury.
Konishi H; Miyauchi K; Onishi A; Suzuki S; Fuchimoto D; Shitara J; Endo H; Wada H; Doi S; Naito R; Ogita M; Dohi T; Kasai T; Daida H
PLoS One; 2020; 15(11):e0241195. PubMed ID: 33201888
[TBL] [Abstract][Full Text] [Related]
11. Antiepileptic Drug-Activated Constitutive Androstane Receptor Inhibits Peroxisome Proliferator-Activated Receptor
Shizu R; Otsuka Y; Ezaki K; Ishii C; Arakawa S; Amaike Y; Abe T; Hosaka T; Sasaki T; Kanno Y; Miyata M; Yamazoe Y; Yoshinari K
Mol Pharmacol; 2020 Nov; 98(5):634-647. PubMed ID: 32892155
[TBL] [Abstract][Full Text] [Related]
12. Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Honda A; Kamata S; Akahane M; Machida Y; Uchii K; Shiiyama Y; Habu Y; Miyawaki S; Kaneko C; Oyama T; Ishii I
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563117
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
[TBL] [Abstract][Full Text] [Related]
14. Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion.
Kitamura S; Murao N; Yokota S; Shimizu M; Ono T; Seino Y; Suzuki A; Maejima Y; Shimomura K
BMC Res Notes; 2023 Sep; 16(1):202. PubMed ID: 37697384
[TBL] [Abstract][Full Text] [Related]
15. Pemafibrate: First Global Approval.
Blair HA
Drugs; 2017 Oct; 77(16):1805-1810. PubMed ID: 28929345
[TBL] [Abstract][Full Text] [Related]
16. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
Fruchart JC; Hermans MP; Fruchart-Najib J; Kodama T
Curr Atheroscler Rep; 2021 Jan; 23(1):3. PubMed ID: 33392801
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: a new mode of ligand recognition and receptor stabilization.
Bernardes A; Souza PC; Muniz JR; Ricci CG; Ayers SD; Parekh NM; Godoy AS; Trivella DB; Reinach P; Webb P; Skaf MS; Polikarpov I
J Mol Biol; 2013 Aug; 425(16):2878-93. PubMed ID: 23707408
[TBL] [Abstract][Full Text] [Related]
18. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
Honda Y; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Fujita K; Yoneda M; Takizawa T; Saito S; Nagashima Y; Nakajima A
Sci Rep; 2017 Feb; 7():42477. PubMed ID: 28195199
[TBL] [Abstract][Full Text] [Related]
19. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
Iitake C; Masuda D; Koseki M; Yamashita S
Cardiovasc Diabetol; 2020 Nov; 19(1):201. PubMed ID: 33246467
[TBL] [Abstract][Full Text] [Related]
20. Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice.
Takei K; Han SI; Murayama Y; Satoh A; Oikawa F; Ohno H; Osaki Y; Matsuzaka T; Sekiya M; Iwasaki H; Yatoh S; Yahagi N; Suzuki H; Yamada N; Nakagawa Y; Shimano H
J Diabetes Investig; 2017 Jul; 8(4):446-452. PubMed ID: 28084058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
